查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1954669

全球药物洗脱球囊导管市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析以及未来预测（2026-2034）

Drug-eluting Balloon Catheters Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 124 Pages | 商品交期: 请询问到货日

价格

药物洗脱球囊导管市场成长驱动因子

2025年全球药物洗脱球囊导管市场规模为7.7805亿美元，预计2026年将达到8.4634亿美元。最终，预计到2034年将成长至20.5326亿美元，2026年至2034年的复合年增长率（CAGR）将达到11.72%。市场成长的主要驱动因素包括心血管疾病盛行率的上升、微创手术的日益普及以及药物洗脱球囊导管（DEBC）相对于传统药物洗脱支架（DES）的优势。

药物洗脱球囊导管（也称为药物涂层球囊导管）是一种先进的医疗器械，它透过充气球囊将抗增殖药物直接输送到血管壁。这种标靶给药方式可以恢復血管腔内的血管生成，治疗动脉粥状硬化和支架内再狭窄，并降低延迟血栓形成的风险，且无需植入永久性装置。该技术能够促进血管壁快速癒合，并抑制平滑肌细胞增殖，因此与药物洗脱支架（DES）相比，它是一种更安全的选择。

市场区隔及主要驱动因素

依药物类型划分，紫杉醇类药物将在2026年占市场主导地位，市占率高达93.72%，市场规模达7.9316亿美元。紫杉醇洗脱球囊导管已确立了稳固的市场地位，新产品的不断推出也持续推动该细分市场的成长。 由于西罗莫司对与动脉粥状硬化相关的缺氧细胞具有强大的抗增殖作用，因此预计该细分市场将实现显着的复合年增长率 (CAGR)，使其适用于治疗血管再狭窄。

依适应症划分，预计到 2026 年，週边血管介入治疗细分市场将占总市场的 76.00%，达到 6.4324 亿美元。这主要得益于週边动脉疾病 (PAD) 盛行率的上升以及针对性产品的上市。冠状动脉介入治疗细分市场预计将以最高的复合年增长率成长，这主要得益于波士顿科学公司紫杉醇涂层 PTCA 球囊导管在日本的临床试验和新产品获批。

依终端用户划分，预计到 2026 年，医院和门诊手术中心 (ASC) 将占最大的市场占有率（66.32%，5.613 亿美元）。这主要归因于医院支出的增加以及患者寻求全面诊断和治疗的趋势。此外，随着导管介入治疗设施的增加，冠状动脉和周边血管治疗的可近性正在扩大，专科诊所和导管介入实验室的数量也将显着增加。

区域趋势

北美将在2025年引领全球市场，占48.84%的市占率（总计3.8004亿美元）。这主要归功于週边动脉疾病（PAD）和冠状动脉疾病（CAD）的高发病率、技术进步以及美敦力（Medtronic）和BD等大型企业的存在。预计到2026年，美国市场规模将达到3.8195亿美元，PAD患者人数预计将达800万至1200万人。

欧洲市场也保持着强劲的地位，德国、法国和英国凭藉其先进的医疗基础设施和不断增长的血管疾病病例，做出了重要贡献。 预计2026年，英国市场规模将达到3,631万美元，德国市场规模预计将达到5,878万美元。

亚太市场预计将以最高的复合年增长率成长，这主要得益于患者对微创手术的偏好日益增强以及週边动脉疾病（PAD）盛行率的上升。预计到2026年，日本、中国和印度的市场规模将分别达到4,138万美元、4,449万美元和1,937万美元。巴西和墨西哥等拉丁美洲国家的PAD病例正在增加，并且获得先进治疗的机会也在增加。儘管仍存在监管方面的挑战，但中东和非洲地区的市场正在逐步普及。

产业主要参与者及趋势

主要市场参与者包括美敦力 (Medtronic)、BD、B. Brown SE、波士顿科学公司 (Boston Scientific Corporation)、飞利浦 (Philips)、微创医疗 (Microport Medical (Group) Inc.)、美林生命科学 (Merrill Life Sciences)、百多力 (Biotronic) 和 Cordis。每家公司都专注于研发和新产品发布，以扩大市场占有率。主要进展如下：

  • 2022年8月：BD启动了首个週边西罗莫司药物洗脱球囊的人体临床试验，以验证其治疗週边动脉疾病 (PAD) 的有效性。
  • 2021年1月：微创医疗的Reewarm PTX DCB PTA导管获得欧盟CE认证，用于股腘动脉介入治疗。
  • 2020年11月：波士顿科学的Ranger DCB获得FDA批准，用于治疗PAD、股浅动脉 (SFA) 和腘动脉 (PPA)。
  • 2019年10月：飞利浦的低剂量药物涂层球囊（DCB）产品Stellarex获得FDA核准。
  • 2017年6月：飞利浦收购Spectranetics以加强其DCB产品线。

市场限制因子

儘管市场呈现成长趋势，但药物涂层球囊（DEBC）的推广应用仍面临挑战。研究表明，在股腘动脉中使用紫杉醇涂层球囊有较高的死亡风险，可能会限制其应用。美敦力已就其IN.PACT AV DCB相关的延迟死亡风险发出警告。 此外，严格的监管，特别是美国FDA批准的冠状动脉药物交换器（DEBC）短缺，可能会阻碍市场扩张。

新冠疫情的影响

疫情暂时降低了需求，导致2020年全球收入下降13.7%。这主要是由于血管成形术数量的减少。波士顿科学公司介入心臟病部门2020年的收入下降了18.4%。 2021年，随着限制措施的放宽和手术的恢復，市场开始復苏，全球对DEBC的需求也在增加。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 週边动脉疾病 (PAD) 盛行率：区域分布（2025 年）
  • 在开发产品分析
  • 新产品发布
  • 主要行业趋势
  • 新冠疫情对市场的影响

第五章 全球药物洗脱球囊导管市场分析：洞察与预测 （2021-2034）

  • 市场分析、洞察与预测：依药物分类
    • 紫杉醇
    • 西罗莫司
    • 其他
  • 市场分析、洞察与预测：依适应症分类
    • 冠状动脉介入治疗
    • 週边血管介入治疗
  • 市场分析、洞察与预测：依最终用户分类
    • 医院及门诊手术中心
    • 专科诊所及导管室
  • 市场分析、洞察与预测：依地区分类
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区（ROW）

第六章 北美药物洗脱球囊导管市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲药物洗脱球囊导管市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 其他欧洲地区

第八章 亚太地区药物洗脱球囊导管市场分析：洞察与预测（2021-2034）

  • 国家细分市场
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚太地区

第九章 其他地区（ROW）药物洗脱球囊导管市场分析：洞察与预测（2021-2034）

第10章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • Medtronic
    • Koninklijke Philips N.V.
    • Boston Scientific Corporation
    • BD
    • B. Braun SE
    • Meril Life Sciences Pvt. Ltd.
    • BIOTRONIK
    • Cordis
    • MicroPort Medical(Group)Co., Ltd.
Product Code: FBI107028

Growth Factors of drug-eluting balloon catheters Market

The global drug-eluting balloon catheters market was valued at USD 778.05 million in 2025 and is projected to reach USD 846.34 million in 2026, eventually growing to USD 2,053.26 million by 2034, representing a robust CAGR of 11.72% during 2026-2034. The market's growth is primarily driven by the rising prevalence of cardiovascular diseases, increasing adoption of minimally invasive procedures, and the advantages of drug-eluting balloon catheters (DEBCs) over traditional drug-eluting stents (DES).

Drug-eluting balloon catheters, also known as drug-coated balloon catheters, are advanced devices that deliver anti-proliferative drugs directly into the vessel wall via inflated balloons. This targeted drug delivery restores luminal vascularity, treats atherosclerosis and in-stent restenosis, and reduces the risk of late thrombosis without leaving a permanent implant. The technology supports rapid healing of the vessel wall and prevents smooth muscle cell proliferation, positioning it as a safer alternative to DES.

Market Segmentation and Key Drivers

By drug type, the paclitaxel segment dominated the market in 2026, accounting for 93.72% of the market with a size of USD 793.16 million. Paclitaxel-eluting balloon catheters have a well-established presence, and the launch of new products continues to drive segment growth. The sirolimus segment is expected to witness a significant CAGR due to its stronger anti-proliferative effect on atherosclerosis-related hypoxic cells, making it suitable for treating vascular restenosis.

In terms of indication, the peripheral intervention segment accounted for 76.00% of the market in 2026, valued at USD 643.24 million, driven by the growing prevalence of peripheral artery disease (PAD) and targeted product launches. The coronary intervention segment is expected to grow at the fastest CAGR, with clinical trials and new product approvals, such as Boston Scientific's Agent paclitaxel-coated PTCA balloon catheter trial in Japan, contributing to growth.

By end-user, hospitals and ambulatory surgical centers (ASCs) held the largest share in 2026, contributing 66.32% of the market (USD 561.3 million), due to higher hospital expenditure and patient preference for comprehensive diagnosis and treatment. Specialty clinics and catheterization laboratories are also expected to expand significantly as more catheterization facilities increase accessibility to coronary and peripheral vascular procedures.

Regional Insights

North America dominated the global market in 2025 with a 48.84% share, totaling USD 380.04 million, due to high PAD and coronary artery disease (CAD) prevalence, technological advancements, and presence of key players like Medtronic and BD. The U.S. market is projected to reach USD 381.95 million by 2026, with 8-12 million people affected by PAD.

Europe also holds a strong position, with Germany, France, and the U.K. contributing significantly due to advanced healthcare infrastructure and rising vascular disease cases. The UK market is projected to reach USD 36.31 million by 2026, while Germany is expected to reach USD 58.78 million.

The Asia Pacific market is projected to grow at the fastest CAGR, driven by increasing patient preference for minimally invasive procedures and rising PAD prevalence. Japan, China, and India are expected to reach USD 41.38 million, USD 44.49 million, and USD 19.37 million, respectively, by 2026. Latin American countries like Brazil and Mexico are witnessing rising PAD cases and improved access to advanced interventions. Gradual adoption is observed in the Middle East & Africa, though regulatory hurdles persist.

Industry Players and Developments

Prominent market players include Medtronic, BD, B. Braun SE, Boston Scientific Corporation, Koninklijke Philips N.V., MicroPort Medical (Group) Co., Ltd., Meril Life Sciences Pvt. Ltd., BIOTRONIK, and Cordis. Companies focus on R&D and new product launches to expand market presence. Notable developments include:

  • August 2022: BD launched a first-in-human trial of a peripheral sirolimus drug-coated balloon to study PAD treatment efficacy.
  • January 2021: MicroPort received EU CE mark for Reewarm PTX DCB PTA catheter for femoral popliteal artery interventions.
  • November 2020: Boston Scientific obtained FDA approval for Ranger DCB to treat PAD, SFA, and PPA.
  • October 2019: Philips received FDA approval for Stellarex low-dose DCBs.
  • June 2017: Philips acquired Spectranetics to enhance its DCB portfolio.

Market Restraints

Despite growth, DEBC adoption faces challenges. Studies highlight high mortality risks with paclitaxel-coated balloons in femoropopliteal arteries, potentially limiting adoption. Medtronic has issued warnings regarding late mortality risks with its IN.PACT AV DCB. Additionally, stringent regulations-particularly the lack of FDA-approved coronary DEBCs in the U.S.-may hinder market expansion.

COVID-19 Impact

The pandemic temporarily reduced demand, with global revenues declining by -13.7% in 2020 due to fewer angioplasty procedures. Boston Scientific experienced an 18.4% revenue drop in interventional cardiology in 2020. Recovery began in 2021 with eased restrictions and resumed procedures, increasing DEBC demand globally.

Conclusion

The drug-eluting balloon catheters market is poised for strong growth from USD 778.05 million in 2025 to USD 2,053.26 million by 2034, driven by rising heart disease prevalence, technological advancements, minimally invasive interventions, and product innovation. While regulatory challenges and safety concerns exist, the market's expansion, particularly in North America and Asia Pacific, signals a promising future for DEBC adoption worldwide.

Segmentation By Drug

  • Paclitaxel
  • Sirolimus
  • Others

By Indication

  • Coronary Intervention
  • Peripheral Intervention

By End-user

  • Hospitals & ASCs
  • Specialty Clinics and Catheterization Laboratories

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Rest of the World

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Peripheral Artery Disease (PAD), in 2025 - By Region
  • 4.2. Pipeline Analysis
  • 4.3. New Product Launches
  • 4.4. Key Industry Developments
  • 4.5. Impact of COVID-19 on the Market

5. Global Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Paclitaxel
    • 5.1.2. Sirolimus
    • 5.1.3. Others
  • 5.2. Market Analysis, Insights and Forecast - By Indication
    • 5.2.1. Coronary intervention
    • 5.2.2. Peripheral intervention
  • 5.3. Market Analysis, Insights and Forecast - By End-user
    • 5.3.1. Hospitals & ASCs
    • 5.3.2. Specialty Clinics and Catheterization Laboratories
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Rest of the World

6. North America Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Paclitaxel
    • 6.1.2. Sirolimus
    • 6.1.3. Others
  • 6.2. Market Analysis, Insights and Forecast - By Indication
    • 6.2.1. Coronary intervention
    • 6.2.2. Peripheral intervention
  • 6.3. Market Analysis, Insights and Forecast - By End-user
    • 6.3.1. Hospitals & ASCs
    • 6.3.2. Specialty Clinics and Catheterization Laboratories
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Paclitaxel
    • 7.1.2. Sirolimus
    • 7.1.3. Others
  • 7.2. Market Analysis, Insights and Forecast - By Indication
    • 7.2.1. Coronary intervention
    • 7.2.2. Peripheral intervention
  • 7.3. Market Analysis, Insights and Forecast - By End-user
    • 7.3.1. Hospitals & ASCs
    • 7.3.2. Specialty Clinics and Catheterization Laboratories
  • 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Spain
    • 7.4.5. Italy
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Paclitaxel
    • 8.1.2. Sirolimus
    • 8.1.3. Others
  • 8.2. Market Analysis, Insights and Forecast - By Indication
    • 8.2.1. Coronary intervention
    • 8.2.2. Peripheral intervention
  • 8.3. Market Analysis, Insights and Forecast - By End-user
    • 8.3.1. Hospitals & ASCs
    • 8.3.2. Specialty Clinics and Catheterization Laboratories
  • 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Rest of the World Drug-eluting Balloon Catheters Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Paclitaxel
    • 9.1.2. Sirolimus
    • 9.1.3. Others
  • 9.2. Market Analysis, Insights and Forecast - By Indication
    • 9.2.1. Coronary intervention
    • 9.2.2. Peripheral intervention
  • 9.3. Market Analysis, Insights and Forecast - By End-user
    • 9.3.1. Hospitals & ASCs
    • 9.3.2. Specialty Clinics and Catheterization Laboratories

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
    • 10.2.1. Medtronic
      • 10.2.1.1. Overview,
      • 10.2.1.2. Product,
      • 10.2.1.3. SWOT Analysis,
      • 10.2.1.4. Recent Developments,
      • 10.2.1.5. Strategies,
      • 10.2.1.6. financials (Based on Availability)
    • 10.2.2. Koninklijke Philips N.V.
      • 10.2.2.1. Overview,
      • 10.2.2.2. Product,
      • 10.2.2.3. SWOT Analysis,
      • 10.2.2.4. Recent Developments,
      • 10.2.2.5. Strategies,
      • 10.2.2.6. financials (Based on Availability)
    • 10.2.3. Boston Scientific Corporation
      • 10.2.3.1. Overview,
      • 10.2.3.2. Product,
      • 10.2.3.3. SWOT Analysis,
      • 10.2.3.4. Recent Developments,
      • 10.2.3.5. Strategies,
      • 10.2.3.6. financials (Based on Availability)
    • 10.2.4. BD
      • 10.2.4.1. Overview,
      • 10.2.4.2. Product,
      • 10.2.4.3. SWOT Analysis,
      • 10.2.4.4. Recent Developments,
      • 10.2.4.5. Strategies,
      • 10.2.4.6. financials (Based on Availability)
    • 10.2.5. B. Braun SE
      • 10.2.5.1. Overview,
      • 10.2.5.2. Product,
      • 10.2.5.3. SWOT Analysis,
      • 10.2.5.4. Recent Developments,
      • 10.2.5.5. Strategies,
      • 10.2.5.6. financials (Based on Availability)
    • 10.2.6. Meril Life Sciences Pvt. Ltd.
      • 10.2.6.1. Overview,
      • 10.2.6.2. Product,
      • 10.2.6.3. SWOT Analysis,
      • 10.2.6.4. Recent Developments,
      • 10.2.6.5. Strategies,
      • 10.2.6.6. financials (Based on Availability)
    • 10.2.7. BIOTRONIK
      • 10.2.7.1. Overview,
      • 10.2.7.2. Product,
      • 10.2.7.3. SWOT Analysis,
      • 10.2.7.4. Recent Developments,
      • 10.2.7.5. Strategies,
      • 10.2.7.6. financials (Based on Availability)
    • 10.2.8. Cordis
      • 10.2.8.1. Overview,
      • 10.2.8.2. Product,
      • 10.2.8.3. SWOT Analysis,
      • 10.2.8.4. Recent Developments,
      • 10.2.8.5. Strategies,
      • 10.2.8.6. financials (Based on Availability)
    • 10.2.9. MicroPort Medical (Group) Co., Ltd.
      • 10.2.9.1. Overview,
      • 10.2.9.2. Product,
      • 10.2.9.3. SWOT Analysis,
      • 10.2.9.4. Recent Developments,
      • 10.2.9.5. Strategies,
      • 10.2.9.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 02: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 03: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 04: Global Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Region, 2025-2034
  • Table 05: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034

North America Market Analysis and Insights, By Indication

  • Figure 08: North America Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 09: North America Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Table 06: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 07: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 08: North America Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country, 2025-2034
  • Table 09: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 10: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 11: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 12: Europe Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country/Sub-region, 2025-2034
  • Table 13: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 14: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 15: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034
  • Table 16: Asia Pacific Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Country/Sub-region, 2025-2034
  • Table 17: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Drug, 2025-2034
  • Table 18: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By Indication, 2025-2034
  • Table 19: Rest of the World Drug-eluting Balloon Catheters Market Revenue (USD million) Forecast, By End-user, 2025-2034

List of Figures

  • Figure 01: Global Drug-eluting Balloon Catheters Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034

Analysis

  • Figure 02: Global Drug-eluting Balloon Catheters Market Value Share (%), By Drug, 2025 & 2034
  • Figure 03: Global Drug-eluting Balloon Catheters Market Value Share (%), By Indication, 2025 & 2034
  • Figure 04: Global Drug-eluting Balloon Catheters Market Value Share (%), By End-user, 2025 & 2034
  • Figure 05: Global Drug-eluting Balloon Catheters Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 07: North America Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 08: North America Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 09: North America Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 10: North America Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 11: North America Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 12: North America Drug-eluting Balloon Catheters Market Value (USD million), by Country, 2025 & 2034
  • Figure 13: North America Drug-eluting Balloon Catheters Market Value Share (%), by Country, 2025
  • Figure 14: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 15: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 16: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 17: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 18: Europe Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 19: Europe Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 20: Europe Drug-eluting Balloon Catheters Market Value (USD million), by Country/Sub-region, 2025 & 2034
  • Figure 21: Europe Drug-eluting Balloon Catheters Market Value Share (%), by Country/Sub-region, 2025
  • Figure 22: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 23: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 24: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 25: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 26: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 27: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 28: Asia Pacific Drug-eluting Balloon Catheters Market Value (USD million), by Country/Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Drug-eluting Balloon Catheters Market Value Share (%), by Country/Sub-region, 2025
  • Figure 30: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by Drug, 2025 & 2034
  • Figure 31: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by Drug, 2025
  • Figure 32: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by Indication, 2025 & 2034
  • Figure 33: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by Indication, 2025
  • Figure 34: Rest of the World Drug-eluting Balloon Catheters Market Value (USD million), by End-user, 2025 & 2034
  • Figure 35: Rest of the World Drug-eluting Balloon Catheters Market Value Share (%), by End-user, 2025
  • Figure 36: Global Drug-eluting Balloon Catheters Market Share (%), By Company, 2025

Analysis